Paris: Sanofi has announced that the AERIFY-1 phase 3 study evaluating itepekimab in former smokers with inadequately ...

Topline results were announced from two phase 3 trials evaluating itepekimab in former smokers with inadequately controlled COPD.

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying ...

Sanofi and Regeneron have reported that the Phase III AERIFY-1 trial of the fully human monoclonal antibody itepekimab.

The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...

RBC Capital analyst Brian Abrahams downgraded Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) to Sector Perform from Outperform, ...

Morgan Stanley has lowered its price target on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) to $755 from $958, while ...

IL-33 inhibitor itepekimab for chronic obstructive pulmonary disease (COPD), and vaccines against acne, extra-intestinal pathogenic Escherichia coli (EPEC), and respiratory syncytial virus (RSV).

which recently generated positive phase 2 data in the Tailwind study – along with Boehringer Ingelheim's cathepsin C Inhibitor BI-1291583 (phase 2), Sanofi's anti-IL-33 antibody itepekimab ...